Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Parini

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Atherosclerosis|August 13, 2024
HDL, reverse cholesterol transport, and atherosclerosis: Unravelling the complexity or adding to the confusion?Paolo Parini
British Journal of Pharmacology|May 29, 2025
The use of different types of networks, alone and in combination, for drug target identificationPaolo Parini
British Journal of Pharmacology|November 18, 2025
Network medicine and network pharmacology: rational approach to drug development for precision therapeuticsPaolo Parini, Joseph Loscalzo
Current Opinion in Lipidology|April 8, 2026
HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading?Paolo Parini, Matteo Pedrelli
Arteriosclerosis, Thrombosis, and Vascular Biology|March 18, 2003
Is there a need for cholesteryl ester transfer protein inhibition?Paolo Parini, Lawrence L Rudel
Journal of Lipid Research|August 2, 2018
Hepatic thyroid hormone receptor β1 agonism: good for lipids, good for bile?Paul A Dawson, Paolo Parini
Atherosclerosis. Supplements|February 8, 2003
Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDLBo Angelin, Paolo Parini, Mats Eriksson
Biochimica Et Biophysica Acta|August 5, 2014
Role of TG-interacting factor (Tgif) in lipid metabolismCamilla Pramfalk, Mats Eriksson, Paolo Parini
World Journal of Gastroenterology|December 16, 2010
Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transportMatteo Pedrelli, Camilla Pramfalk, Paolo Parini
The Heart Surgery Forum|June 17, 2011
Late cardiac tamponade by chylous pericardial effusion after coronary artery bypass surgery: case reportAnders Albåge, Gösta Eggertsen, Paolo Parini
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Atherosclerosis|August 13, 2024
HDL, reverse cholesterol transport, and atherosclerosis: Unravelling the complexity or adding to the confusion?Paolo Parini
British Journal of Pharmacology|May 29, 2025
The use of different types of networks, alone and in combination, for drug target identificationPaolo Parini
British Journal of Pharmacology|November 18, 2025
Network medicine and network pharmacology: rational approach to drug development for precision therapeuticsPaolo Parini, Joseph Loscalzo
Current Opinion in Lipidology|April 8, 2026
HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading?Paolo Parini, Matteo Pedrelli
Arteriosclerosis, Thrombosis, and Vascular Biology|March 18, 2003
Is there a need for cholesteryl ester transfer protein inhibition?Paolo Parini, Lawrence L Rudel
Journal of Lipid Research|August 2, 2018
Hepatic thyroid hormone receptor β1 agonism: good for lipids, good for bile?Paul A Dawson, Paolo Parini
Atherosclerosis. Supplements|February 8, 2003
Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDLBo Angelin, Paolo Parini, Mats Eriksson
Biochimica Et Biophysica Acta|August 5, 2014
Role of TG-interacting factor (Tgif) in lipid metabolismCamilla Pramfalk, Mats Eriksson, Paolo Parini
World Journal of Gastroenterology|December 16, 2010
Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transportMatteo Pedrelli, Camilla Pramfalk, Paolo Parini
The Heart Surgery Forum|June 17, 2011
Late cardiac tamponade by chylous pericardial effusion after coronary artery bypass surgery: case reportAnders Albåge, Gösta Eggertsen, Paolo Parini
Pageof 14